Company Overview - Hims and Hers transformed from a startup selling Viagra to a telehealth company valued at almost $11 billion [1] - The company attracted approximately 4 million subscribers, representing about 2.4%, through celebrity-backed ads and virtual doctor prescriptions [1] Strategic Decisions - Hims and Hers entered the weight loss shot market, selling a copycat version at a discount due to shortages of drugs like WGO and Zepbound [2] - The decision to sell compounded weight loss drugs could be costly and polarize investors [3] Financial Performance & Market Reaction - Hims and Hers' stock reached a high of nearly $70 in February 2025 but has since declined [2] - The company's "wild ride" has attracted meme stock investors [3]

Economic Impact - Weight-loss drugs are fueling economic growth in Denmark [1] - Local retailers are warning of a hit due to declining food consumption [1]

It does for weight loss. Its other supposed benefits are debatable https://t.co/xQzp2TuGLN ...

they're going to lose the listing either way. >> Yeah. But potentially good news for the US and the administration and other health care news.Some big changes are underway in the weight loss space. Starting today, CVS health will prioritize Novo Nordisk's Wegovy as the pharmacy's preferred GLP one drug and dropping Zepp from its list of covered drugs and a potential blow to Eli Lilly. Joining us now is Mizuho Healthcare strategist Jared Holt.Why does it have to be one or the other. Jared. >> Hey, Sara.Thank ...

Core Insights - Omada Health's GLP-1 companion program significantly enhances medication persistence rates for GLP-1 medications, leading to improved weight loss outcomes comparable to clinical trials [1][2][4] Group 1: Medication Persistence and Weight Loss - Omada's analysis of 1,124 members showed that those who adhered to their GLP-1 medication for 24 weeks had a persistence rate of 84%, compared to lower rates in previous studies [2][4] - Members who maintained their medication lost an average of 12.1% of their body weight over 24 weeks, while those who discontinued early lost only 7.4%, indicating a 64% relative increase in weight loss for persistent users [2][4] Group 2: Support and Resources - The Enhanced GLP-1 Care Track provides targeted resources, including education on dose titration, side effects, nutrition guidance, and exercise support, to help members overcome barriers to medication persistence [3][4] - Omada aims to ensure that increased access to GLP-1 medications translates into sustainable long-term health benefits through enhanced support and engagement in healthy lifestyle changes [4][5] Group 3: Company Overview and Impact - Omada Health is a virtual-first healthcare provider focused on chronic disease management, with over a decade of experience and 29 peer-reviewed publications demonstrating its clinical and economic effectiveness [5][6] - The company serves more than 2,000 customers, including health plans and employers, and emphasizes a strong work culture, earning recognition as a Great Place to Work® [5][6]

Investor Presentation March 2025 Disclaimer This presentation, the information contained herein and the materials accompanying it (together, this "presentation") contains confidential, material and non-public information regarding Allurion Technologies, Inc. (the "Company" or "us") and is provided to the recipients ("you") of this presentation on the condition that you agree to hold it in strict confidence and not reproduce, disclose, forward or distribute it in whole or in part to others at any time withou ...